Roche Holding AG
ROG.S- Latest Trade
- trading lower316.95CHF
- Change
- -1.4
- % Change
0.44%Negative
- As of Aug 11 2022. Values delayed up to 15 minutes
- Day Range
- 315.60 - 319.45
- 52-Week Range
- 298.30 - 404.20
- Previous Close
- 318.35
- Open
- 317.60
- Volume
- 625,440.00
- 3 Month Average Trading Volume
- 24.24
- Shares Out (Mil)
- 800.58
- Market Cap
- 265,611.80
- Forward P/E
- 15.38
- Dividend Yield
- 2.92
Key Statistics
2.28571429 mean rating - 28 analysts
- P/E Excl. Extra Items (TTM)
- 18.01
- Price To Sales (TTM)
- 4.13
- Price To Book (Quarterly)
- 10.12
- Price To Cash Flow (Per Share TTM)
- 13.31
- Total Debt/Total Equity (Quarterly)
- 110.17
- Long Term Debt/Equity (Quarterly)
- 88.80
- Return On Investment (TTM)
- 27.70
- Return On Equity (TTM)
- 18.19
2021 (millions USD)
About Roche Holding AG (ROG.S)
Company Information
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Address
Grenzacherstrasse 124BASEL,
4058
Switzerland
Industry
Major Drugs
Executive Leadership
- Christoph Franz
- Non-Executive Independent Chairman of the Board
- Severin Schwan
- Chief Executive Officer, Executive Director, Member of the Corporate Executive
- Andre S. Hoffmann
- Non-Executive Independent Vice Chairman of the Board
- Alan Hippe
- Member of the Corporate Executive Committee, Chief Financial and Information Officer
- Cristina A. Wilbur
- Member of the Corporate Executive Committee, Chief People Officer
- Pascale Schmidt
- Chief Compliance Officer
- Claudia Boeckstiegel
- Member of the Enlarged Corporate Executive Committee, General Counsel
- William N. Anderson
- Member of the Corporate Executive Committee, Chief Executive Officer of Roche Pharmaceuticals
- William Pao
- Member of the Enlarged Corporate Executive Committee, Head Roche Pharma Research and Early Development (pRED)
- Aviv Regev
- Member of the Enlarged Corporate Executive Committee, Head Genentech Research and Early Development (gRED)
- James H. Sabry
- Member of the Enlarged Corporate Executive Committee, Global Head Pharma Partnering
- Barbara Schaedler
- Member of the Enlarged Corporate Executive Committee, Head Group Communications
- Thomas Schinecker
- Member of the Corporate Executive Committee, Chief Executive Officer of Roche Diagnostics
- Per-Olof Attinger
- Secretary to the Corporate Executive Committee
- Annette Luther
- Secretary to the Board of Directors
- Julie Brown
- Non-Executive Independent Director
- Paul Bulcke
- Non-Executive Independent Director
- Hans Clevers
- Non-Executive Independent Director
- Joerg Duschmale
- Non-Executive Independent Director
- Patrick Frost
- Non-Executive Independent Director
- Anita Hauser
- Non-Executive Independent Director
- Richard P. Lifton
- Non-Executive Independent Director
- Bernard J. Poussot
- Non-Executive Independent Director
- Claudia Suessmuth Dyckerhoff
- Non-Executive Independent Director
Latest News
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,795.60 | -- |
| Copper | 669.70 | 0.91%Positive |
| Brent Crude Oil | 96.95 | 0.46%Negative |
| CBOT Soybeans | 1,688.75 | -- |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,210.24 | 2.13%Positive |
| Euro STOXX 50 | 3,749.35 | 0.91%Positive |
| FTSE 100 | 7,507.11 | 0.25%Positive |
| Nikkei 225 | 27,819.33 | 0.65%Negative |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes